We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+37.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.62B
AUM Growth
+$630M
(+32%)
Cap. Flow
+$142M
Cap. Flow
% of AUM
5.42%
Top 10 Holdings %
Top 10 Hldgs %
54.13%
Holding
172
New
46
Increased
29
Reduced
19
Closed
33
Avg Time Held Equity + Options
4.2
quarters
Top 10 Avg Time Held Equity + Options
5.4
quarters
Top 20 Avg Time Held Equity + Options
5.4
quarters
Avg Time Held Equity only
4.4
quarters
Top 10 Avg Time Held Equity only
5.4
quarters
Top 20 Avg Time Held Equity only
5.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$64.1M |
| 2 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$36.1M |
| 3 |
XLRN
Acceleron Pharma
XLRN
|
+$31.4M |
| 4 |
Puma Biotechnology
PBYI
|
+$17.7M |
| 5 |
Cymabay Therapeutics
CBAY
|
+$15.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$42.4M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$36.7M |
| 3 |
Radius Health, Inc.
RDUS
|
+$29.2M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$20.9M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.22% |
| 2 | Miscellaneous | 1.22% |
| 3 | Industrials | 0.33% |
| 4 | Consumer Staples | 0.16% |
| 5 | Consumer Discretionary | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
MYOK
26
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $23.6M | 0.9% |
550,717
-2,437
| -0.4% | -$77.7K |
2015 Q4
7 quarters
|
|
27
Aldeyra Therapeutics
ALDX
$54.6M
| $22.2M | 0.85% |
3,085,458
+200,000
| +7% | +$1.04M |
2015 Q1
10 quarters
|
|
28
DELISTED
Audentes Therapeutics, Inc
BOLD
| $21.9M | 0.84% |
781,309
+73,809
| +10% | +$1.6M |
2016 Q3
4 quarters
|
|
29
Cartesian Therapeutics
RNAC
$211M
| $21.2M | 0.81% |
38,744
+12,166
| +46% | +$6.47M |
2016 Q2
5 quarters
|
|
|
30
Vertex Pharmaceuticals
VRTX
$129B
| $21.1M | 0.81% |
138,626
-138,726
| -50% | -$20.9M |
2015 Q4
7 quarters
|
|
31
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.94B
| $21M | 0.8% |
206,405
-20,000
| -9% | -$1.75M |
2016 Q4
3 quarters
|
|
32
iRhythm Holdings
IRTC
$3.52B
| $19.3M | 0.74% |
372,671
+89,814
| +32% | +$4.07M |
2016 Q4
3 quarters
|
|
|
33
DELISTED
Cymabay Therapeutics
CBAY
| $18.9M | 0.72% |
+2,350,882
| New | +$15.9M |
2017 Q3
0 quarters
|
|
|
QTNT
34
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $18.4M | 0.7% |
93,175
+313
| +0.3% | +$62.5K |
2014 Q2
13 quarters
|
|
|
ALBO
35
DELISTED
Albireo Pharma Inc
ALBO
| $17.7M | 0.68% |
845,000
| – | – |
2017 Q2
1 quarter
|
|
|
NVTA
36
DELISTED
Invitae Corporation
NVTA
| $17.7M | 0.67% |
1,884,500
+1,235,000
| +190% | +$11.7M |
2016 Q4
3 quarters
|
|
|
KDMN
37
DELISTED
Kadmon Holdings, Inc.
KDMN
| $17.4M | 0.66% |
5,185,847
| – | – |
2016 Q3
4 quarters
|
|
|
AVDL
38
DELISTED
Avadel Pharmaceuticals
AVDL
| $16.3M | 0.62% |
1,549,005
+119,891
| +8% | +$1.14M |
2016 Q3
4 quarters
|
|
|
ONCE
39
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $16M | 0.61% |
+180,000
| New | +$13.7M |
2017 Q3
0 quarters
|
|
40
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
| $15.8M | 0.61% |
1,259,636
| – | – |
2015 Q2
9 quarters
|
|
|
ADYX
41
DELISTED
Adynxx Inc
ADYX
| $15.5M | 0.59% |
70,566
| – | – |
2014 Q4
11 quarters
|
|
42
Assembly Biosciences
ASMB
$464M
| $15.4M | 0.59% |
36,819
| – | – |
2015 Q1
10 quarters
|
|
43
Evolent Health
EVH
$481M
| $15.1M | 0.58% |
850,000
-224,327
| -21% | -$4.62M |
2015 Q2
9 quarters
|
|
44
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $14.7M | 0.56% |
+929,460
| New | +$13.6M |
2017 Q3
0 quarters
|
|
|
ATRS
45
DELISTED
Antares Pharma, Inc.
ATRS
| $14.1M | 0.54% |
4,353,897
+86,644
| +2% | +$267K |
2016 Q3
4 quarters
|
|
46
Wave Life Sciences
WVE
$646M
| $14M | 0.53% |
642,798
-20,000
| -3% | -$402K |
2016 Q1
6 quarters
|
|
47
Teleflex
TFX
$5.33B
| $13.4M | 0.51% |
+55,200
| New | +$12M |
2017 Q3
0 quarters
|
|
48
DELISTED
Synlogic
SYBX
| $13.1M | 0.5% |
+45,757
| New | +$9.36M |
2017 Q3
0 quarters
|
|
|
AVEO
49
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $12.6M | 0.48% |
341,512
-259,554
| -43% | -$8.03M |
2016 Q2
5 quarters
|
|
50
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $11.4M | 0.44% |
306,134
+186,134
| +155% | +$5.65M |
2017 Q2
1 quarter
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q3 2017 Portfolio in Review
As of Q3 2017, Perceptive Advisors held 172 positions worth $2.62B, up 32% from $1.99B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Perceptive Advisors deployed $142M of net new capital in Q3 2017, opening 46 new positions and adding to 29 existing holdings. Its largest new stake was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Aravive, Inc. Common Stock, an estimated $42.4M trimmed.
- Perceptive Advisors's largest Q3 2017 buy was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
- Perceptive Advisors added most to Neurocrine Biosciences in Q3 2017, an estimated $64.1M increase.
- Perceptive Advisors's biggest Q3 2017 reduction was Aravive, Inc. Common Stock, cutting an estimated $42.4M.
- Perceptive Advisors fully exited Sarepta Therapeutics in Q3 2017, selling an estimated $36.7M.
- Perceptive Advisors's ten largest holdings make up 54% of its $2.62B portfolio in Q3 2017.
- Perceptive Advisors opened 46 new positions and closed 33 in Q3 2017.
- Perceptive Advisors's portfolio value rose 32% quarter-over-quarter to $2.62B.
Based on Perceptive Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.